Objective To observe the clinical effect of dapagliflozin combined with metformin and acarbose in the treatment of type 2 diabetes mellitus（T2DM） with poor glycemic control. Methods One hundred and four patients with T2DM with poor glycemic control admitted to a hospital in Henan province from May 2019 to February 2021 were enrolled as study subjects. The patients were divided into an observation group（n=52） and a control group（n=52） using the random number table method. Patients in both groups were given menthol insulin treatment according to their blood glucose levels. Meanwhile

patients in the control group were given metformin + acarbose treatment. Patients in the observation group were given dapagliflozin treatment based on the treatment of patients in the control group. The levels of glycosylated hemoglobin Alc（Hb Acl）

2 h postprandial blood glucose（2 h PBG）

fasting blood glucose（FBG）

triglycerides（TG）

total cholesterol（TC）

high-density lipoprotein cholesterol（HDL-C） and low-density lipoprotein cholesterol（LDL-C） before and after treatment were compared between the two groups. The waist circumference and body mass of the 2 groups of patients were compared before and after treatment. The mean daily dose of menadione insulin during treatment was compared between the 2 groups. Results Before treatment

there was no statistically significant difference between the FBG

Hb Acl and 2 h PBG levels of the 2 groups of patients（P>0.05）; after treatment

the FBG

Hb Acl and 2 h PBG levels of the 2 groups of patients were lower than those before treatment and lower in the observation group than in the control group

with statistically significant differences（P<0.05）. Before treatment

there was no statistically significant difference between the TC

HDL-C and LDL-C levels of the 2 groups of patients（P>0.05）. After treatment

there was no significant difference in TC

HDL-C and LDL-C levels of the 2 groups compared with those before treatment（P>0.05）

while the TG levels of patients in the observation group were significantly lower than those in the control group after treatment

with statistically significant differences（P<0.05）. Before treatment

there was no statistically significant difference in body mass and waist circumference between the 2 groups of patients（P>0.05）. After treatment

the body mass and waist circumference of patients in the observation group were smaller than those before treatment and smaller than those in the control group

and the difference was statistically significant（P<0.05）. The differences were not statistically significant when comparing the body mass and waist circumference of patients in the control group before and after treatment（P>0.05）.The mean daily dose of menadione insulin in the observation group was smaller than that in the control group

and the difference was statistically significant（P<0.05）.Conclusion The efficacy of dagliflozin + metformin and acarbose in the treatment of T2DM with poor glycemic control is evident. It can effectively and significantly control patients’ blood glucose

regulate blood lipid level

reduce body mass and insulin dosage

and is worthy of wider clinical practice.